SCHEMBL3074483

SCHEMBL3074483

Cc1ccc(NC(=O)c2cccc(C(F)(F)F)c2)cc1C(N)=O

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LCK P06239 7/20 0.71
BTK Q06187 7/20 0.71
MAPK14 Q16539 2/20 0.71
KDR P35968 1/20 0.71
KIT P10721 2/20 0.71
ABL1 P00519 1/20 0.71
SRC P12931 1/20 0.71
BRAF P15056 4/20 0.68
CSF1R P07333 3/20 0.68
MEN1 O00255 1/20 0.65
HTT P42858 1/20 0.65
RAB9A P51151 1/20 0.65
KMT2A Q03164 1/20 0.65
CYP2C9 P11712 1/20 0.65
KCNK3 O14649 2/20 0.64
KCNK9 Q9NPC2 1/20 0.64
PTGS1 P23219 2/20 0.63
BLK P51451 1/20 0.62
MAPT P10636 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3084639 0.90 MAPK14 (0.71) LCKBTKMAPK14KDRKIT
SCHEMBL2501251 0.89 LCK (0.72) LCKBTKMAPK14KDRKIT
SCHEMBL3941263 0.87 LCK (0.69) LCKBTKMAPK14KDRKIT
SCHEMBL18618394 0.87 LCK (0.69) LCKBTKMAPK14KDRKIT
SCHEMBL12858422 0.86 MEN1 (0.73) LCKBTKMAPK14KDRKIT
SCHEMBL374471 0.85 PTGS1 (0.70) LCKBTKMAPK14KDRKIT
SCHEMBL4421970 0.84 CSF1R (0.55) LCKBTKMAPK14KDRKIT
Hydrochloric Acid SCHEMBL5004557 0.84 PTGS1 (0.68) LCKBTKMAPK14KDRKIT
SCHEMBL18758915 0.84 LCK (0.69) LCKBTKMAPK14KDRKIT
SCHEMBL24249928 0.84 MEN1 (0.70) LCKBTKMAPK14KDRKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3912973-A2 SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE Dana-Farber Cancer Institute, Inc. (US) 2021-11-24 EP claimed
EP-3150593-A1 SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE Dana Farber Cancer Institute, Inc. (US) 2017-04-05 EP claimed
US-8921336-B2 Small molecule myristate inhibitors of BCR-ABL and methods of use DANA-FARBER CANCER INSTITUTE, INC. (US) 2014-12-30 US claimed
US-20110053932-A1 Protein Kinase Inhibitors and Methods for Using Thereof IRM LLC 2011-03-03 US claimed
US-7795273-B2 Pyrazolo[1,5-a]pyridine-3-carboxylic acids as EphB and VEGFR2 kinase inhibitors NOVARTIS AG (CH) 2010-09-14 US claimed
EP-2222162-A2 SMALL MOLECULE MYRISTATE INHIBITORS OF BCR-ABL AND METHODS OF USE Dana Farber Cancer Institute (US) 2010-09-01 EP claimed
US-20100093821-A1 3-Amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases HOLZER PHILIPP 2010-04-15 US claimed
EP-2170842-A1 PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF IRM, LLC (BM) 2010-04-07 EP claimed
US-7589101-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2009-09-15 US claimed
EP-2079745-A1 3-AMINOCARBONYI-SUBSTITUTED FUSED PYRAZOLO-DERIVATIVES AS PROTEIN KINASE MODULATORS Novartis AG (CH) 2009-07-22 EP claimed
WO-2008052974-A1 3-AMINO-PYRAZOLE-4-CARBOXAMIDE DERIVATIVES USEFUL AS INHIBITORS OF PROTEIN KINASES NOVARTIS AG (CH) 2008-05-08 WO claimed
EP-1918291-A1 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators Novartis AG (CH) 2008-05-07 EP claimed
US-7338957-B2 Compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2008-03-04 US claimed
EP-1841431-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM, LLC (BM) 2007-10-10 EP claimed
WO-2007065664-A2 PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXYLIC ACIDS AS EPHB AND VEGFR2 KINASE INHIBITORS NOVARTIS AG (CH) 2007-06-14 WO claimed
JP-2007504159-A 2007-03-01 JP claimed
WO-2007022268-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-02-22 WO claimed
WO-2006081172-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-08-03 WO claimed
EP-1658290-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-05-24 EP claimed
WO-2005039486-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2005-05-06 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053932-A1 Protein Kinase Inhibitors and Methods for Using Thereof BMX, FRK, FYN LCK 9/4885BTK 7/4885MAPK14 387/4885
US-20100093821-A1 3-Amino-pyrazole-4-carboxamide derivatives useful as inhibitors of protein kinases MAP4K2, MAP4K3, MAP4K1 LCK 299/4885BTK 435/4885MAPK14 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.